HRT for Menopause: What a Clinic Program Looks Like

The indications are on the drug labels.

Premarin (conjugated estrogens) tablets, an FDA-approved menopausal hormone product, are indicated for moderate-to-severe hot flashes (vasomotor symptoms) due to menopause, moderate-to-severe vulvar and vaginal atrophy due to menopause, and prevention of postmenopausal osteoporosis, among other uses.

The Menopause Society's 2022 position statement is blunt: hormone therapy is the most effective treatment for vasomotor symptoms (hot flashes) and the genitourinary syndrome of menopause, and it has been shown to prevent bone loss and fracture.

Vaginal symptoms can be treated on their own.

For genitourinary symptoms alone, the same statement recommends low-dose vaginal estrogen or other therapies — vaginal DHEA or oral ospemifene — when over-the-counter products are not enough and systemic therapy is not otherwise indicated.

Just as useful is what that Premarin label does not list: energy, libido, weight loss and "anti-aging" are not among its indicated uses.

If a program markets hormone therapy for those goals, that use is not on the product's label.

The timing framework comes from the Menopause Society's 2022 position statement: for women younger than 60 or within 10 years of menopause who have no contraindications, the benefit-risk ratio is favorable for treating bothersome hot flashes and preventing bone loss.

The labels name the contraindications — the conditions where the product should not be used.

Premarin's label, for example, lists undiagnosed abnormal genital bleeding, current or past breast cancer (except selected metastatic cases), estrogen-dependent cancers, current or past blood clots (DVT/PE), stroke or heart attack, liver disease, and inherited clotting disorders.

Screening for those conditions is why an HRT conversation should start with a full medical history: the label's contraindications are the people the product should not be used on, and weighing your own history against that list is a licensed clinician's call.

FDA's 2025 labeling request points in the same direction as the 2022 statement, asking that systemic product labels add consideration of starting hormone therapy for moderate-to-severe hot flashes in women under 60 or within 10 years of menopause.

Two distinctions do most of the work in menopausal hormone therapy.

The first is systemic versus local: FDA's 2025 labeling request refers to "systemic" products as a group, and the Menopause Society treats low-dose vaginal estrogen as its own category for genitourinary symptoms alone.

The second is estrogen-alone versus estrogen plus a progestogen — the two arms the Women's Health Initiative tested, and one of the factors the Menopause Society says changes HRT's risk profile, along with the type, dose, duration and route of therapy and the timing of initiation.

Our hormone replacement therapy guide covers the dosage forms in detail — tablets, pellets, the compounded "bioidentical" question, who may prescribe and what the labels say — so this page stays on the menopause-specific picture above.

The age question is anchored by the Women's Health Initiative, which randomized 27,347 postmenopausal women aged 50 to 79 (mean age 63) in 1993-1998 to estrogen plus progestin (median 5.6 years) or estrogen alone (median 7.2 years) versus placebo.

FDA says the estrogen-plus-progestin trial was stopped in 2002 after an increased risk of breast cancer was reported, and the estrogen-alone trial in 2004 for increased stroke risk and no heart-disease prevention — and that the participants averaged 63 years old, older than women typically starting HRT, since the average age at menopause in the US is 51.

The 18-year follow-up, published in JAMA in 2017, found no association between the hormone assignments and all-cause, cardiovascular or cancer mortality.

On timing, the Menopause Society's position is that starting more than 10 years after menopause or after age 60 is less favorable, because the absolute risks of heart disease, stroke, blood clots and dementia are higher at those starting points.

FDA moved on the labels in November 2025.

On November 10, 2025, FDA announced it was initiating removal of the boxed-warning language on cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy labels, while keeping the boxed warning on endometrial cancer for systemic estrogen-alone products.

The same labeling request removes the "lowest effective dose for the shortest time" recommendation from the boxed warning and adds, for systemic products, consideration of starting hormone therapy for moderate-to-severe hot flashes in women under 60 or within 10 years of menopause — while cardiovascular and breast cancer warnings are retained elsewhere in the label.

Updates roll out product by product: Premarin's DailyMed label effective June 4, 2026 still carried a boxed warning for endometrial cancer, cardiovascular disorders, breast cancer and probable dementia.

Watch the press-release numbers too.

HHS's November 2025 press release claimed women starting HRT within 10 years of menopause may reduce their cardiovascular disease risk "by as much as 50%," Alzheimer's disease by 35%, and fractures by 50 to 60%.

Those are HHS statements, not label claims — and HRT is not FDA-approved to prevent heart disease or dementia.

The useful comparison is not the address but the prescribing and the screening around it: our research found no study comparing menopause outcomes between med spa programs and OB-GYN practices, so we can't tell you that one setting treats menopause better than the other.

On prescribing: our research did not find a federal rule naming who may prescribe HRT at a med spa or wellness clinic; who may prescribe — a physician (MD or DO), a nurse practitioner (NP) or a physician associate/assistant (PA) — and under what supervision is a state-law question.

Ask any clinic directly which clinician writes the prescription and how supervision works, and check your state's rules.

What to look for is the same in either setting: a history and screening against the label's contraindications, a named product — an FDA-approved drug with its label, or a plainly disclosed compounded preparation — and a follow-up plan.

A program that skips the contraindication screening is skipping the part of the label that decides who should not take the drug.

For the pieces this page hands off — who may prescribe, which labs a program runs, compounded "bioidentical" hormones versus FDA-approved ones, and how programs are priced — see our hormone replacement therapy guide.

Vetting an HRT program is mostly a prescribing question, and the specifics are worth getting in writing before you pay:

That general vetting — credentials to look for, red flags, ownership and supervision — is what our how to choose a med spa checklist walks through.

Nothing on this page is a recommendation for or against hormone therapy.

The labeled indications, the timing framework and the contraindications above are the material to bring into a conversation with a licensed clinician who can see your full history.